D activity in o er strains tha promoter tha most importa that the bacte nhibition of th membrane stre non-specific d ded as the sole ermeabilize m ations. 12 been shown potently inhibi een establish he observed a ve the molec old been iden by preparing 4 ( Figure 1B to probe the impact of the substitution pattern, we synthesized monocyclic analogues 3a-c ( Figure 1C ) and substituted derivatives 2a-i and 4a-e ( Figure 1B-D) , respectively. To circumvent possible decomposition of the acid and base-labile enol cyclocarbamate during synthesis, 15 we developed a novel route in which the enol cyclocarbamate is introduced at a late stage in the synthesis and that allows straightforward functionalization of this labile scaffold in the final step with copper-catalyzed click chemistry. With the panel of molecules synthesized, we identified the structural features that are required for antibacterial activity. Using metabolic labeling and activity-based protein profiling, we reveal that these enol cyclocarbamates interfere with peptidoglycan synthesis and that they inhibit Class A high molecular weight penicillin-binding proteins.
Results and discussion

Chemical synthesis
The synthesis of the panel of enol carbamate derivatives commenced with condensing Meldrum's acid to Boc-protected building blocks 5, 8, 11 and 15a-b (Scheme 1A-D) using N,N'dicyclohexylcarbodiimide (DCC) and 4-(dimethylamino)pyridine (DMAP). Filtration and subsequent acid-base extraction gave the crude Meldrum's acid derivative intermediates. Attempts to directly convert these into β-keto amides using five equivalents of amine in refluxing toluene resulted in complex mixtures and the β-keto amide was therefore installed using a two-step procedure. First, the Meldrum's acid intermediates were smoothly converted into the corresponding β-keto esters 6, 9, 12 and 16a-b by refluxing the intermediates in anhydrous methanol. 16 In a second step, the β-keto esters were reacted with the amine of interest to form β-keto amides 7a-d, 10, 13 and 17a-b.
Refluxing β-keto ester 6 with hexylamine or benzylamine in THF did not result in the desired β-keto amide products 7b and 7c, but afforded the corresponding enamine products instead. The same, undesired products were obtained when the β-keto esters were reacted with the amine in the presence of sodium methoxide 17 or titanium isopropoxide. 18 Traces of the desired β-keto amides could be obtained by treating the amine with trimethylaluminum to generate the dimethylaluminum amide in situ. 19 We therefore turned our attention to DABAL-Me 3 , the adduct of 1,4-diazabicyclo[2.2.2]octane (DABCO) and trimethylaluminum. 20, 21 Activating the amine in this fashion improved the yield of the β-keto amide formation reaction and products 7a-d, 10, 13 and 17a-b were obtained in moderate to reasonable yields. The final steps of the synthesis entailed the deprotection and formation of the enol cyclocarbamate. Although removal of the Boc-protecting group with hydrogen chloride in diethyl ether and subsequent cyclization of the precipitated hydrochloride salt with carbonyldiimidazole (CDI) gave the enol cyclocarbamates as separable mixture of E and Z isomers, the moderate yield prompted us to devise a novel two-step one-pot procedure. Deprotecting β-keto amides 7ad, 10, 13 and 17a-b with trimethylsilyl trifluoromethanesulfonate (TMSOTf) in CH 2 Cl 2 was directly followed by cyclization with CDI affording the lipocyclocarbamates 2a-d, 3a, 3c and 4a-b. After silica gel column chromatography, the Z-isomers were obtained as pure products. Large-scale synthesis of 3a, 3c and 4b revealed that a minor isomer was also formed and for 3c both isomers were isolated. NOE (Nuclear Overhauser Effect) experiments with Scheme 1. Synthesis of enol carbamates starting from (A) Boc-proline (B) Boc-glycine (C) Boc-sarcosine (D) N-Boc-4-hydroxyproline. Reagents and conditions: (i) Meldrum's acid, DCC, DMAP; (ii) MeOH, reflux (yield over 2 steps: 54-85%); (iii) DABCO, AlMe 3 , amine (dodecylamine for 7a, 10, 13, 17a and 17b; hexylamine for 7b; benzylamine for 7c; propargyl amine for 7d) (yield: 36-73%); (iv) TMSOTf then CDI (yield over 2 steps: 34 -55%); (v) CuSO 4 , sodium ascorbate, alkyl azide (dodecyl azide for 2e, 4-phenylbenzyl azide for 2f, 6azidohexanol for 2g, phytyl azide for 2h; biotin azide for 2i; benzyl azide for 4c; 2-(2-(2-azidoethoxy)ethoxy)ethanol for 3b and 4d; 3-azido-N,N-dimethylpropan-1-amine for 4e) (yield: 29-68%); (vi) NaH, Br-R (benzyl bromide for 15a; propargyl bromide for 15b) (yield: 90%). these isomers confirmed that the Z enol carbamate is formed preferentially. Moreover, the chemical shifts for the isomers are in accordance with the values reported in the literature for similar structures. 15 The diversity of the panel of enol cyclocarbamates was increased further via a copper-catalyzed click reaction. Alkyne 2d was reacted with dodecyl azide, 6azidohexanol, phytyl azide, 4-phenylbenzyl azide and biotin azide to obtain compounds 2e-i that differ in chain. Reacting Z-lipocyclocarbamate 4b with benzyl azide, 2-(2-(2azidoethoxy)ethoxy)ethanol and 3-azido-N,N-dimethylpropan-1-amine led to derivatives 4c, 4d and 4e, respectively. Finally, Z-lipocyclocarbamate 3a was reacted with (2-(2azidoethoxy)ethoxy)ethanol to obtain monocyclic compound 3b.
Antibacterial activity of enol carbamates
The biological activity of the panel of enol cyclocarbamates 2ai, 3a-c and 4a-e was determined using a standardized liquid-media based MIC (minimum inhibitory concentration) assay. 22 Since lipopeptide 1a was shown to be particularly potent against Gram-positive bacteria, 12, 23 we initially focused on discriminating between active and non-active compounds on the Gram-positive model bacterium Bacillus subtilis 168. Cells were cultured in the presence of serial dilutions of the compound for 20 hours, after which both the optical density (OD 600 ) and resazurin were used to evaluate the activity of the compound. Metabolically active bacteria convert resazurin into highly fluorescent resorufin and the viability of the bacteria in the presence of the enol cyclocarbamates can be determined by comparing the fluorescence intensity of B. subtilis cells treated with compound to the fluorescence intensity of control cells treated with 0.05% DMSO (Figure 2A and Figure S1 ). 24 Of the synthesized compounds, bicyclic enol carbamates 2a, 2e, 4d and 4e inhibit bacterial growth as judged by OD 600 and by resazurin, with the respective MIC values being 50 M for 2a and 2e and 400 M for 4d and 4e. The corresponding monocyclic analogues 3a-c do not affect the viability of B. subtilis, indicating that the 5,5-fused bicyclic ring system is indispensable for potent inhibition of bacterial growth. Besides the bicyclic enol carbamate, also the substitution pattern has a large effect on the activity. Active compounds 2a, 2e, 4d and 4e all bear a long, linear alkyl chain and replacing this group by smaller and more polar substituents leads to a significant reduction in antibacterial activity. Hexyl amide derivative 2b, benzyl amide 2c and propargyl amide 2d do not show any activity under the conditions used. Interestingly, the activity of propargyl amide 2d can be restored by reacting it with dodecylazide to form derivative 2e. However, other hydrophobic groups, such as the 4-phenylbenzyl in 2f and the phytyl in 2h, do not restore the activity and the introduction of more polar substituents, such as the hexylalcohol in 2g and the biotin in 2i, also leads to inactive compounds. Substituents at other positions of the bicyclic ring system result in remarkable behavior. Both benzyl ether 4a and propargyl ether 4b do not show any activity and functionalization of propargyl ether 4b with benzyl azide, as in 4c also leads to an inactive compound. However, equipping 4b with a polyethylene glycol (PEG), as in 4d, or with a tertiary amine, as in 4e, results in compounds with moderate activity. Although the amphiphilic nature of these compounds may account for part of the activity, it is likely that the activity of 4d is not solely caused by its surfactant-like properties. This reasoning is reinforced by the fact that PEGylated monocyclic 3b, which is derived from inactive compound 3a and structurally related to 4d, does not show activity in the MIC assay, and it thus underlines the importance of the 5,5-fused bicyclic scaffold for the antibacterial activity. We subsequently tested the activity of 2a, 2e, 4d and 4e on the Gram-positive opportunistic human pathogen Streptococcus pneumoniae, which is annually responsible for killing more than 1 million people and in which antibiotic resistance is on the rise. Culturing S. pneumoniae strain D39 with these compounds for 20 hours revealed that only compounds 2a or 2e had an effect on the viability of this bacterium, with the MIC value being 400 M. We then studied the bacterial growth to determine whether the active compounds 2a, 2e, 4d and 4e are bacteriostatic, bactericidal or bacteriolytic. Several compounds that showed to be inactive in the MIC assay (3c, 4a and 4b) were used in these experiments as controls. Starting with an inoculum of OD 600 0.02 for B. subtilis orOD 595 0.04 for S. pneumoniae strain D39, with or without the compounds, the optical density was monitored over time. As expected, monocyclic derivative 3c and bicyclic benzyl ether 4a, which are inactive in the MIC assay, do not inhibit bacterial growth when evaluated at the same concentrations as the active compounds (compare growth curves Figure 2B , C and Figure S2 with Figure S3 ). Bicyclic propargyl ether 4b, which was inactive in the MIC assay at 400 M, did slow down growth at higher concentration. The cells started to grow after prolonged Figure S8 ). Also in this strain, compounds 2a and 4d block fluorescent labeling. In S. pneumoniae and B. subtilis, penicillin-binding proteins (PBPs) incorporate HADA 6, 29 and other fluorescent D-amino acids (FDAAs) [30] [31] [32] onto the stempeptide of lipid II and peptidoglycan and the decrease in HADA labeling suggests that the enol carbamates inhibit this process. To establish which PBPs are inhibited by the enol carbamates, we performed competitive activity-based protein-profiling experiments. Cells were incubated with the enol carbamates for 60 minutes prior to cell lysis and the addition of Bocillin FL, a fluorescent penicillin derivative that labels the majority of the PBPs in B. subtilis (Figure 4 ). Fluorescent scanning of the gels revealed that propargyl amide 2d does not inhibit labeling of PBPs, but dodecyl amide 2a blocks labeling of a Bocillin FL-sensitive PBP ( Figure 4A ) with an approximate molecular weight of 70 kDa in concentration-dependent manner. The molecular weight of this PBP could correspond to PBP3, PBP4, or PBP4A.
Complemented strains that express PBP-GFP fusions and PBPnull strains were used to determine which of these PBPs is inhibited by the enol carbamates. 33, 34 The PBP-GFP fusion proteins migrate differently on the SDS-PAGE due to the increase in molecular weight and as a consequence the Bocillin FL labeling pattern will alter. In null strains, the fluorescent band of the respective PBP will be absent when labeling these cells with Bocillin FL. Labeling of PBP-GFP strains did not result in noticeable differences, but labeling of the PBP4-null strain with Bocillin FL, gave a pattern that corresponds with wild type B. subtilis treated with 2a, indicating that this compound inhibits PBP4 ( Figure 4B ). Profiling experiments with the complete panel of enol carbamates revealed that compounds 4d and 4e, and to lesser extend 2e also block labeling of PBP4 ( Figure S9 and S10). We subsequently studied if the enol carbamates also target PBPs in S. pneumoniae D39 using the same activity-based protein-profiling experiment as described for B. subtilis. The dodecyl amide 2a, propargyl amide 2d and monocyclic analogue 3c were added to a mid-log culture of S. pneumoniae D39, before the cells were lysed and reacted with Bocillin FL. Incubating lysates from cells that were treated with 4% DMSO, as a control, results in three fluorescent bands with a molecular weight of 79, 73 and 45 kDa. These bands correspond with PBP1a/1b, PBP2a/2b/2x and PBP3, respectively. Addition of 2d or 3c to the medium does not alter the labeling profile, but incubating S. pneumoniae with dodecyl amide 2a reduces the labeling intensity of the PBP1a/1b and PBP3 bands by 40 and 60%, respectively ( Figure 4C and Figure  S11 ). Concomitantly, a new fluorescent band (around 40-43 kDa) appears when cells are incubated with 2a or 4b ( Figure  4C ). It has been reported that some antibiotics increase the sensitivity of S. pneumoniae PBPs to proteolysis and this band therefore could be formed by proteolytic cleavage of one of the PBPs reacting with 2a. Alternatively, the band could be caused by aberrant running of a PBP that reacted with both Bocillin FL and 2a. 35 The addition of phenylmethylsulfonyl fluoride (PSMF), a broad-spectrum serine hydrolase inhibitor, during the incubation steps does not block the formation of the band ( Figure S11 ). The biological relevance of this labeled protein will have to be determined. The identified Class A high-molecular weight PBPs, which have glycosyltransferase and transpeptidase activity, are not essential for B. subtilis and S. pneumoniae viability. Deletion of PBP4 in B. subtilis 36 and PBP1a or PBP1b in S. pneumoniae 37, 38 does not affect growth and cell-wall synthesis and inhibition of 39 Contrary to enol carbamates 2a and 4d, which completely block septal incorporation of HADA in wild type B. subtilis, septal labeling of the PBP4-null strain with HADA is not altered ( Figure S12 ). The latter observation corroborates the results of Fura et al., who showed that FITC-D-lysine is incorporated at the septum of a PBP4-null strain. 39 These results clearly demonstrate that the observed decrease in septal labeling in B. subtilis is not caused by exclusive inhibition of PBP4. This conclusion is reinforced by the observation that labeling of the septum can be inhibited by treating PBP4-null cells with 2a ( Figure S12 ). We therefore hypothesize that enol carbamates 2a and 4d do not only inhibit PBP4 in B. subtilis, but that they also inhibit other enzymes in the peptidoglycan synthesis pathway, these being PBPs that are not labeled by Bocillin FL or other enzymes that are directly or indirectly involved in the synthesis of lipid II and the peptidoglycan. This hypothesis is supported by unpublished data from our lab, which revealed that antibiotics that inhibit enzymes upstream of the PBPs block incorporation of HADA. Similarly, these compounds may inhibit peptidoglycan synthesis directly or indirectly in S. pneumoniae and we are currently identifying these additional targets.
Conclusions
In conclusion, we developed a synthetic route that yielded a panel of enol cyclocarbamates containing compounds in four or five steps. By studying the biological activity of these compounds in a MIC assay, we showed that the bicyclic scaffold and the dodecyl alkyl chain are indispensable for antibacterial activity. Modifications on the bicyclic headgroup are tolerated, but small changes in the functional group can lead to complete loss of activity. Growth-curve experiments, time-lapse microscopy and metabolic labeling with HADA revealed that enol cyclocarbamates inhibit peptidoglycan synthesis (i.e., they are bacteriolytic). Using activity-based protein-profiling experiments, we demonstrated for the first time that compounds containing an enol cyclocarbamate inhibit a specific subset of PBPs in two Gram-positive species of bacteria, B. subtilis and S. pneumoniae. While inhibition of these PBPs may contribute to the inhibition of HADA incorporation, the enol cyclocarbamates likely also target other enzymes involved in peptidoglycan synthesis. This makes the scaffold an attractive starting point in the search for novel antibiotics.
Experimental Chemicals
Resazurin sodium salt was purchased from BD Biosciences. Syto9 and Propidium Iodide were purchased from Life Technologies. All the other chemicals were purchased from Sigma-Aldrich. The synthesized enol cyclocarbamate compounds were dissolved in DMSO and were stored at -20 °C.
Bacterial strains B. subtilis strain 168 was cultured in lysogeny broth (LB). The strain was first grown in LB overnight at 37 °C before the MIC assay or the optical density (OD 600 ) assay. The MIC assay itself was performed in cation adjusted Mueller-Hinton medium. B. subtilis PBP4-null strain was constructed by transformation of chromosomal DNA from strain PS2022 (pbpD::Erm) to B. subtilis 168 with selection for erythromycin resistance. Correct chromosomal insertion was verified by PCR and the absence of PBP4 in a Bocillin-FL PBP profile. 36 S. pneumoniae D39 strain (serotype 2) was grown at 37 °C in C+Y medium with 2% acid (pH 6.8) until a mid-exponential phase (OD 595 of 0.4). 40 The cells were centrifuged for 2 minutes at 20,800 rcf and the cell pellet was resuspended in a volume of fresh medium containing 14.5% glycerol (v/v) that would result in an OD 595 of 0.4. The cells were then aliquoted and stored at -80 °C. These mid-exponential phase cell stocks will be referred to as T2 cells. Please do not adjust margins Please do not adjust margins and were grown until OD 0.4 in C+Y with 2% acid. For the assay, this pre-culture was diluted 100-fold in C+Y and incubated in microtiter plates with or without different concentrations of the antimicrobials. Growth (OD 595 ) was measured every 10 minutes in a Tecan Infinite F200 PRO with at least three replicates for each condition.
MIC determination
Microscopy
Inhibition of incorporation of the fluorescent D-amino-acid analogue HADA into peptidoglycan in live B. subtilis was determined using a wide-field fluorescence microscope. B. subtilis 168 was diluted from an overnight culture to an OD 600 of 0.02 in casein hydrolysate medium 41 and grown at 37 °C until an OD 600 of 0.2, at which point the compounds were added to the medium. Cells were incubated for 20 minutes with compound, followed by 5 minutes labeling with HADA (0.5 mM), after which cells were fixed with 70% ethanol. Bacteria were imaged under a Nikon Ti-E inverted microscope equipped with a CFI Plan Apochromat DM 100× oil objective, using appropriate filter sets for the dyes used. Digital images were recorded using a Hamamatsu Orca Flash 4.0 (V2) camera and prepared using Adobe Photoshop. -Lysates from B. subtilis 168 and B. subtilis PBP4-null strains were prepared in the following way: cells were diluted from an overnight culture to an OD of 0.1 and cultured until OD 0.3 (usually 2 hours), washed two times with PBS, lysozyme (0.5 mg/mL) was added and cells were sonicated (10 seconds pulse, 10 seconds stop (10 times) in order to control the temperature), lysates were then flash-frozen using liquid nitrogen. Lysates (19 μL, 1 mg/mL protein content) was incubated with or without compound for 60 minutes.
Activity
-S. pneumoniae was cultured to mid-exponential phase, cells (4 mL per lane) were collected by centrifugation (5 minutes, 20 800 rcf) and resuspend in PBS and incubated with or without compounds during 60 minutes (2.5 % DMSO), cells were then lysed in the presence of lysozyme (0.2 mg/mL, 37°C, overnight) and DNAse (0.1 mg/mL).
For both strains: Lysates were then incubated with Bocillin-FL (45 nM) during 30 minutes at 37°C. Laemmli sample buffer (SP) containing dithiothreitol (DTT) was added and the proteins were resolved on a 12% SDS-PAGE and fluorescence was visualized using a Typhoon scanner.
Synthetic procedures
General remarks. All reactions were performed using oven-dried glassware under an atmosphere of nitrogen (unless otherwise specified) using dry solvents. Reaction temperature refers to the temperature of the oil bath. Solvents were taken from a MBraun solvent purification system (SPS-800). All other reagents were purchased from Sigma Aldrich and Acros and used without further purification unless noted otherwise. Trimethylsilyl trifluoromethanesulfonate was stored under a nitrogen atmosphere in a dry Schlenk flask. TLC analysis was performed on Merck silica gel 60/Kieselguhr F254, 0.25 mm. Compounds were visualized using either ninhydrine stain (ninhydrin (1.5 g) and AcOH (3 mL) in n-butanol (100 mL)) or a KMnO 4 stain (K 2 CO 3 (40 g), KMnO 4 (6 g), H 2 O (600 mL) and 10% NaOH (5 mL)). Flash chromatography was performed using SiliCycle silica gel type SiliaFlash P60 (230 -400 mesh) as obtained from Screening Devices or with automated column chromatography using a Reveleris flash purification system purchased from Grace Davison Discovery Sciences. 1 7a-d, 9, 10, 12, 13,  15a-b, 16a-b and 17a-b ) at 25 °C in DMSO-d 6 mixtures of rotamers and enol-keto tautomers are observed in the NMR spectra and the chemical shifts of these mixtures are reported in the experimental section. While recording the 13 C spectra at 75 °C does solve this issue in part, it comes at the cost of a reduced sensitivity (several carbonyl peaks are not observed in these spectra). We included both the 13 C NMR spectra recorded at 25 °C and at 75 °C in the Supporting Information for the majority of the compounds. For the 1 H NMR of these compounds, measuring the spectra in DMSO-d 6 at 75 °C reduced the presence of rotamers, but it resulted in a poor resolution (multiplicity of the peaks is difficult to observe). In CDCl 3 the multiplicity could be observed, but with presence of rotamers; for the sake of comparison and clarity, the majority is reported in DMSO-d 6 .
General procedure A for O-alkylation of 4-hydroxy Boc-Proline.
A solution of 4-hydroxy Boc-Proline (1 eq) in dry THF was treated with sodium hydride (2.2 eq, 60% in mineral oil). The resulting mixture was stirred at 0 °C for 1 h and the corresponding alkyl bromide (1.1 eq) was added. The reaction mixture was stirred until complete consumption of the starting material was observed and then acidified to pH 3 by the addition of 2 M HCl and subsequently the reaction mixture was extracted with diethyl ether (3 x 20 mL). The combined organic layers were washed with brine (2 x 20 mL), dried over Na 2 SO 4 , and concentrated under reduced pressure. The crude material was purified by silica gel flash column chromatography using Please do not adjust margins Please do not adjust margins ethyl acetate: pentane: AcOH as eluent.
General procedure B for the synthesis of β-keto ester compounds. To a solution of N-Boc-protected Amino-Acid (1 eq) in dry THF was added N,N'-dicyclohexylcarbodiimide (DCC) (1.1 eq) at 0 °C. The reaction mixture was stirred for 2 minutes and 4-dimethylaminopyridine (DMAP) (1.5 eq) and Meldrum´s acid (2,2-dimethyl-1,3-dioxane-4,6-dione) (1.2 eq) were added. The reaction mixture was stirred overnight at room temperature. Diethyl ether (30 mL) was then added to the reaction mixture and the solution was stirred for 10 minutes. After filtration over paper filter, the filtrate was washed with an aqueous Na 2 CO 3 solution (60 mL), the aqueous solution was then acidified to pH 3 with 2 M HCl and the product was extracted with diethyl ether (4 x 30 mL). The organic layer was dried over Na 2 SO 4 and concentrated under reduced pressure. The crude intermediate was dissolved in MeOH (20 mL) and stirred at reflux overnight. The crude mixture was finally concentrated under reduced pressure and purified by silica gel flash column chromatography using ethyl acetate: pentane as eluent.
General procedure C for the synthesis of β-ketoamide compounds. The amidation of unactivated esters was based on the procedure described by Novak et al. 20 A solution of 1,4diazabicyclo[2.2.2]octane (DABCO) (1.2 eq) in dry toluene was cooled to 0 °C and trimethylaluminium (2.4 eq, 2 m in toluene) was added dropwise. The mixture was stirred for 4 hours at 0 °C. A solution of alkyl amine (1.2 eq) in THF was added and the reaction mixture was heated to 40 °C and stirred for 2 h. Subsequently the corresponding β-keto ester (1 eq) dissolved in THF was added and the reaction mixture was stirred overnight at reflux. The reaction mixture was diluted with diethyl ether (15 mL), quenched by adding 2 M HCl dropwise and washed with 2 M HCl (2 x 20 mL). The organic layer was finally dried over Na 2 SO 4 , concentrated under reduced pressure and purified by silica gel flash column chromatography using ethyl acetate: pentane as eluent affording the β-ketoamide compounds.
General procedure D for the synthesis of enol cyclocarbamate compounds. A solution of the corresponding β-ketoamide (1 eq) in DCM was cooled to 0 °C before trimethylsilyl trifluoromethanesulfonate (TMSOTf) (2 eq) was added. The reaction mixture was stirred for 3-4 hours. TLC analysis showed that all starting material had been consumed and therefore 1,1'-carbonyldiimidazole (CDI) (1.5 eq) was added and the reaction mixture was stirred overnight. The reaction mixture was directly applied on silica gel column and flash column chromatography using ethyl acetate: pentane as eluent afforded the lipocyclocarbamate compound.
General procedure E for the synthesis of triazole compounds via Huisgen Azide-Alkyne Cycloaddition. To a solution of the enol cyclocarbamate (1 eq) and corresponding azide (1 eq Hz, 3H). 13 Propargyl β-ketoamide 7d. β-Ketoamide 7d was prepared according to the general procedure C by reacting DABCO (246 mg, 2.2 mmol, 1.2 eq) with trimethylaluminium (2.2 mL, 4.4 mmol, 2.4 eq, 2 M in toluene) in toluene (4 mL) to produce DABAL in situ, subsequently adding propargyl amine (145 μL, 2.2 mmol, 1.2 eq) in THF (3 mL) to activate the amine and finally adding β-ketoester 6 (500 mg, 1.83 mmol, 1 eq) in THF (3 mL 
6-Hydroxyhexyl-triazolyl derivative 2g. Triazole compound 2g
was prepared according to the general procedure E using the enol cyclocarbamate 2d (15.46 mg, 0.07 mmol, 1 eq) and 6azidohexanol (10 mg, 0.07 mmol, 1 eq). ). 13 
N-Boc-N-propargyl glycine 8.
A solution of Boc-Gly-OH (1.75 g, 10 mmol, 1 eq) in dry THF (40 mL) was treated with NaH (0.88 g, 60% in mineral oil, 22 mmol, 2.2 eq.). The resulting mixture was stirred at 0° C for 1 hour and propargyl bromide (80 wt. % in toluene, 1.23 mL, 11 mmol, 1.1 eq.) was added. After overnight stirring at room temperature, TLC analysis showed incomplete conversion and an additional amount of NaH (0.5 equiv.) and propargyl bromide (0.5 equiv.) were added at 0° C. The reaction was stirred overnight at room temperature upon which full conversion of starting material was observed. The reaction mixture was then acidified to pH 3 by addition of 2 M HCl and subsequently was extracted with diethyl ether (3 x 50 mL). The combined organic layers were washed with brine (3 x 100 mL), dried over Na 2 SO 4 , and concentrated under reduced pressure. The crude material was purified by silica gel flash chromatography using ethyl acetate: pentane: AcOH (10: 189: 1) as eluent to give 8 (2.12 g, 99 %) as a light brown oil. -N-propargyl β-ketoester 9 . β-Ketoester 9 was prepared according to the general procedure B using 2-((tertbutoxycarbonyl)(prop-2-yn-1-yl)amino)acetic acid 8 (2.12 g, 9.9 mmol, 1 eq) DCC (2.22 g, 10.8 mmol, 1.1 eq), DMAP (1.65 g, 13.5 mmol, 1.5 eq), Meldrum's acid (1.56 g, 10.8 mmol, 1.1 eq) in THF (50 mL) and subsequent refluxing with MeOH. Flash chromatography using ethyl acetate: pentane (1: 11.5) as eluent gave title compound 9 ( PEG-functionalized monocyclic derivative 3b. Triazole compound 3b was prepared according to the general procedure E using the enol cyclocarbamate 3a-Z (4 mg, 0.012 mmol, 1 eq) and polyethylene glycol azide (3 mg, 0.017 mmol, 1.4 eq). Flash chromatography using ethyl acetate: pentane 
N-Boc
N-Boc-trans-4-propargyloxy-L-proline β-ketoamide 17b. β-
Ketoamide 17b was prepared according to the general procedure C by reacting DABCO (489 mg, 4.36 mmol, 1.3 eq) with trimethylaluminium (4.36 mL, 8.72 mmol, 2.6 eq, 2 M in toluene) in toluene (8 mL) to produce DABAL in situ, subsequently adding dodecylamine (808 mg, 4.36 mmol, 1.3 eq) in THF (4 mL) to activate the amine and finally adding the corresponding β-ketoester 13b (1.09 g, 3.09 mmol, 1 eq) in THF (4 mL 
trans-4-benzyloxy-L-proline derivative 4a.
Enol cyclocarbamate 4a was prepared according to the general procedure D by reacting the appropriate β-keto amide 17a (112.5 mg, 0.19 mmol, 1 eq), TMSOTf (71 μL, 0.39 mmol, 2 eq) and CDI (54 mg, 0.29 mmol, 1.5 eq) in DCM (1 mL). 
trans-4-propargyloxy-L-proline derivative 4b.
Enol cyclocarbamate 4b was prepared according to the general procedure D by reacting the appropriate β-keto amide 17b (130 mg, 0.27 mmol, 1 eq), TMSOTf (98.8 μL, 0.54 mmol, 2 eq) and CDI (75.4 mg, 0.4 mmol, 1.5 eq) in DCM (1.5 mL). Flash chromatography using ethyl acetate: pentane (from 1:4 to 3:2) 1 (t, J = 6.6 Hz, 3H). 13 
